Collaboration and licensing agreement for NPT200-11Collaboration and Licensing Agreement • February 3rd, 2022
Neuropore Therapies has earned a milestone payment related to its collaboration with UCB and the evaluation of UCB0599 for the treatment of Parkinson’s Disease. UCB0599 is an orally administered small molecule alpha-synuclein misfolding inhibitor arising from a Collaboration and License Agreement entered into between Neuropore Therapies and UCB Biopharma on December 31, 2014.
Collaboration and licensing agreement for NPT200-11Collaboration and Licensing Agreement • February 3rd, 2022
Neuropore Therapies has earned a milestone payment related to its collaboration with UCB and the evaluation of UCB0599 for the treatment of Parkinson’s Disease. UCB0599 is an orally administered small molecule alpha-synuclein misfolding inhibitor arising from a Collaboration and License Agreement entered into between Neuropore Therapies and UCB Biopharma on December 31, 2014.